Wait do you meana) takeover of the whole companyb) selling of...

Wait do you mean
a) takeover of the whole company
b) selling of the OA indication asset
c) commercial partnership similar to other products like tanezumab

IMO a) and b) are highly unlikely given the amount of money they would be leaving on the table. They are also the best equipped people to execute the upcoming trial successfully. The whole point of the CR was so that they wouldn't be at the financial mercy of anyone till the end of the trial. I'm sure there are other ways to hedge against currency movements. I also think Paul is more focused on leaving a legacy of discovering a new treatment which was the reason for starting Paradigm in the first place, he could've lived happily ever after in his previous job. What better way than helping conquer the last frontier in big disease. Chairman also had a pretty senior position at CSL. Although you never know.. anyone is capable of anything if the price is right I guess..

c) is a much more likely possibility, not sure when. The train of thought might be the longer they wait, the better the terms will be.